- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02791685
Smartphone Delivered In-home Cardiopulmonary Rehabilitation
Study Overview
Status
Conditions
Detailed Description
This project aims to determine if a smartphone-delivered cardiac rehabilitation (CR) program could show similar clinical outcomes to in-person programs at a low cost in a large population of patients. Investigators will also assess the feasibility of tailoring a virtual CR program to a small sample of COPD participants who also stand to benefit in the absence of an established pulmonary rehabilitation (PR) program.
This is a non-randomized clinical trial of participants at the Atlanta Veterans Affairs Medical Center with an applicable diagnosis for cardiac or pulmonary rehabilitation versus usual care during the study period. We will evaluate the outcomes related to smartphone-enabled home base cardiopulmonary rehabilitation in those who choose the intervention and those who opt into home-based CR, traditional CR, or those who decline. Data from the past 5 years will also be evaluated to obtain a baseline event rate.
Investigators seek to address the following:
- Determine whether a home-based cardiac or pulmonary rehabilitation program delivered through smartphones is feasible and improves functional status.
- Determine if education and lifestyle counseling lead to increased adherence with prescribed follow-up, pharmacotherapy, quality of life, self-efficacy and lifestyle changes.
- Determine if a home-based cardiac or pulmonary rehabilitation program reduces health system utilization, including ED visits and readmission rates.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30033
- Atlanta VA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Meet eligibility for cardiac rehabilitation program as defined by Centers for Medicare & Medicaid Services (CMS); they may also have stable CAD and be referred for cardiac rehab by their provider.
- Following acute myocardial infarction (within the preceding 12 months)
- Coronary artery bypass grafting (CABG)
- Current stable angina pectoris
- Heart valve repair or replacement
- Percutaneous transluminal coronary angioplasty (PTCA) or coronary stenting
- Heart or heart-lung transplant
- Other diagnosis by specific physician referral
Exclusion Criteria:
- Unstable angina
- Resting systolic blood pressure >200 mm Hg or resting diastolic blood pressure >110 mm Hg
- Significant drop (>=20 mm Hg) in resting systolic blood pressure from the patient's average level that cannot be explained by medications
- Moderate to severe aortic stenosis
- Acute systemic illness or fever
- Uncontrolled atrial or ventricular arrhythmias
- Symptomatic congestive heart failure (stage C)
- Third-degree heart block without pacemaker
- Active pericarditis or myocarditis
- Recent venous thromboembolism (VTE, as determined by physician)
- Current Thrombophlebitis
- Uncontrolled diabetes (A1c > 7.0 or as determined by physician)
- Orthopedic problems that would prohibit exercise
- Other by specific physician instruction
- Peripheral vascular disease (PVD; symptomatic or that would prohibit exercise)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cardiac Rehabilitation - Movn Program
Participants with coronary artery disease (CAD) and chronic obstructive pulmonary disease (COPD) who are eligible for cardiac rehabilitation will undergo an in-home program.
|
MULTIFIT is a cardiac rehabilitation program delivered by the Movn smartphone application that will provide risk factor modification, prescribed exercises, education and counseling.
The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management.
Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors.
The program will last for 12 weeks.
|
Experimental: Pulmonary Rehabilitation - Movn Program
Participants with stable chronic obstructive pulmonary disease (COPD) or hospitalized with an acute exacerbation of COPD will undergo an in-home pulmonary rehabilitation program.
|
Movn pulmonary rehabilitation is a program delivered by the Movn smartphone application that includes targeted educational content and prescribed exercises with mild resistance training in addition to walking and other cardiovascular exercises.
The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management.
Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors.
The program will last for 12 weeks.
|
Active Comparator: Traditional Cardiac Rehabilitation
Participants enrolled in a facility's traditional cardiac rehabilitation program will be seen at baseline and during a 12 and 24 week follow-up visit.
|
Standard cardiac rehabilitation involves a facility's standard rehabilitation practices.
Participants will be seen at baseline and during a 12 and 24 week follow-up visit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Functional Capacity assessed by the Six Minute Walk Test (6MWT)
Time Frame: Week 12, Week 24
|
The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface.
The goal is for the individual to walk as far as possible in six minutes.
The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway.
|
Week 12, Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Measure of Exercise Intensity (MET)
Time Frame: Baseline, Week 12
|
An exercise test will be used to collect MET.
|
Baseline, Week 12
|
Change in Weight
Time Frame: Baseline, Week 12
|
Weight will be measured in kilograms.
|
Baseline, Week 12
|
Change in Body Mass Index (BMI)
Time Frame: Baseline, Week 12
|
Body Mass Index (BMI) is a person's weight in kilograms divided by the square of height in meters.
A high BMI can be an indicator of high body fatness.
|
Baseline, Week 12
|
Change in Blood Pressure
Time Frame: Baseline, Week 12
|
Blood pressure is measured using a blood pressure cuff to the upper extremity. The top number, which is also the higher of the two numbers, measures the pressure in the arteries when the heart beats (systolic).The bottom number, which is also the lower of the two numbers, measures the pressure in the arteries between heartbeats (diastolic). Readings are measured as follows: Normal = systolic less than 120 and diastolic less than 80 Prehypertension = systolic 120 - 139 or diastolic 80 - 89 High Blood Pressure (Hypertension) Stage 1 = systolic 140 - 159 or diastolic 90 - 99 High Blood Pressure(Hypertension) Stage 2 = systolic 160 or higher or diastolic 100 or higher Hypertensive Crisis (Emergency care needed) systolic = higher than 180 or diastolic higher than 110 |
Baseline, Week 12
|
Change in A1c Level
Time Frame: Baseline, Week 12
|
The A1C test is a blood test that provides information about a person's average levels of blood glucose, also called blood sugar, over the past 3 months. Levels are measured as follows: Normal = below 5.7 percent Diabetes = 6.5 percent or above Prediabetes = 5.7 to 6.4 percent |
Baseline, Week 12
|
Change in Low-density Lipoprotein (LDL) Level
Time Frame: Baseline, Week 12
|
LDL cholesterol is considered "bad" cholesterol because it contributes to plaque, a thick, hard deposit that can clog arteries and make them less flexible. Levels are measured as follows: < 100 mg/ dL = Optimal 100-129 mg/dL = Near optimal/above optimal 130-159 mg/dL = Borderline high 160-189 mg/dL = High >190 mg/dL = Very high |
Baseline, Week 12
|
Change in Duke Activity Status Index (DASI) Score
Time Frame: Baseline, Week 12
|
The Duke Activity Status Index (DASI) is a 12-item questionnaire that utilizes self-reported physical work capacity to estimate peak metabolic equivalents.
The DASI is scored by adding all activities performed together.
A higher score indicates the ability to perform more physical activities.
|
Baseline, Week 12
|
Change in Patient Health Questionnaire (PHQ-9) Score
Time Frame: Baseline, Week 12
|
The PHQ-9 is an instrument for screening, diagnosing, monitoring, and measuring the severity of depression. Score ranges from 5-9 indicate minimal depressive symptoms. Scores 10-14 may indicate minor depression, dysthymia, and mild major depression. Scores 15-19 indicate moderately severe, major depression. Scores greater than or equal to 20 indicate severe major depression. |
Baseline, Week 12
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Amit J Shah, MD, Emory University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00085938
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on MULTIFIT Cardiac Rehabilitation
-
Wake Forest University Health SciencesRecruitingCardiac AmyloidosisUnited States
-
Lawson Health Research InstituteHeart and Stroke Foundation of OntarioCompleted
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Heart DiseaseUnited States
-
Lawson Health Research InstituteCanadian Institutes of Health Research (CIHR); AstraZenecaCompletedMyocardial Infarction | Coronary Disease | Unstable AnginaCanada
-
Cairo UniversityNational Heart Institute, EgyptCompletedChronic Heart FailureEgypt
-
University of California, San FranciscoPatient-Centered Outcomes Research Institute; Johns Hopkins University; Mayo... and other collaboratorsRecruitingMyocardial Infarction | Coronary Artery Disease | Heart Valve Diseases | Angina, Stable | Heart Failure, Systolic | Heart TransplantUnited States
-
Federico II UniversityCompletedAcute Myocardial InfarctionItaly
-
Women's College HospitalRecruiting
-
Fundación Pública Andaluza para la Investigación...UnknownHomebased Cardiac Rehabilitation Program After Ischemic Heart DiseaseSpain
-
Universidade do PortoCentro Hospitalar de Vila Nova de Gaia/Espinho; Research Center in Physical...CompletedCoronary Artery DiseasePortugal